With an aging population, the burden of kidney disease gradually occupies more and more medical resources. Between 2013 and 2016, chronic kidney disease (CKD) was reported in 14.8% of the United States (US) general adult population. As of December 31, 2016, there are 2,160.7 patients with end stage renal disease (ESRD) per 1,000,000 US citizens, according to the US Renal Data System's latest Annual Data Report [1]. Therefore, there is an urgent demand for effective drugs to delay kidney impairment.Beyond its hypoglycemic action, metformin has pleiotropic protective effects in various disease models, including polycystic ovary syndrome [2], cancer [3], neurological disorders [4], and kidney disease [5]. In particular, emerging evidence has demonstrated potential protective effects of metformin on acute kidney injury (AKI), CKD, diabetic kidney disease (DKD), autosomal dominant (adult) polycystic kidney disease (ADPKD), lupus nephritis (LN), renal neoplasm, and kidney transplantation [6][7][8][9][10][11][12].Metformin protects the kidneys mainly via AMPactivated protein kinase (AMPK) signaling and AMPKindependent pathways. AMPK is a well-known energy and nutrient sensor, which regulates the switch from anabolic to catabolic metabolism to control energy homeostasis [13]. Many kidney diseases are intertwined with abnormal metabolic status, such as hyperglycemia, hyperlipidemia, and hyperuricemia. And many studies has explored the relationship between depressed AMPK activity and kidney disease [14][15][16], revealing that the AMPK agonist metformin exerts protective actions in a variety of kidney disease models, including those induced by hyperglycemia, advanced glycation end products (AGEs), proteinuria, and high fatty www.aging-us.com